Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib

Leukemia and Lymphoma

Volumn 50, Issue 12, 2009, Pages 2017-2029

  Dumka, Disha ^a   Puri, Poonam ^a   Carayol, Nathalie ^b,c   Lumby, Crystal ^a   Balachandran, Harikrishnan ^a   Schuster, Katja ^a   Verma, Amit K ^d   Terada, Lance S ^a   Platanias, Leonidas C ^b,c   Parmar, Simrit ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

CML; Dasatinib; P38 Map kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BCR ABL PROTEIN; DASATINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MIXED LINEAGE KINASE 3; STRESS ACTIVATED PROTEIN KINASE 1;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT; DRUG EFFICACY; DRUG INHIBITION; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAP KINASE KINASE 3; MAP KINASE KINASE 6; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THIAZOLES;

EID: 72949116167     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903147637     Document Type: Article

References (48)

1. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol 2007;44:S25-S31.
2. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-1464.
3. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ ABL and is required for the growth of Philadelphia chromosome- positive cells. Blood 1995;86:726-736.
4. Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997;15:2333-2342.
5. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-254.
6. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997;16:6151-6161.
7. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005;65:2047-2053.
8. Kharas MG, Deane JA, Wong S, et al. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 2004;103:4268-4275.
9. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002;2:351-360.
10. Jagani Z, Singh A, Khosravi-Far R. FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta 2008;1785:63-84.
11. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
12. Palandri F, Iacobucci I, Martinelli G, et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 2008;26:106-111.
13. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-2309. (Pubitemid 46425867)
14. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
15. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125.
16. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-3475.
17. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698.
18. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/ Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004;279:34227-34239.
19. Hochhaus A. Management of Bcr-Abl-positive leukemias with dasatinib. Expert Rev Anticancer Ther 2007;7:1529-1536.
20. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
21. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541. (Pubitemid 43882349)
22. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007;109:4006-4015.
23. Parmar S, Katsoulidis E, Verma A, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABLexpressing cells. J Biol Chem 2004;279:25345-25352.
24. Parmar S, Smith J, Sassano A, et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNa) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 2005;106:2436-2443.
25. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975;45:321-334.
26. Yanagisawa K, Yamauchi H, Kaneko M, Kohno H, Hasegawa H, Fujita S. Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha. Blood 1998;91:641-648.
27. Scappini B, Gatto S, Onida F, et al. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 2004;100:1459-1471.
28. Griswold IJ, MacPartlin M, Bumm T, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006;26:6082-6093.
29. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003;101:3236-3239.
30. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975;66:188-193.
31. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265:808-811.
32. McCoy CE, Campbell DG, Deak M, Bloomberg GB, Arthur JS. MSK1 activity is controlled by multiple phosphorylation sites. Biochem J 2005;387:507-517.
33. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 1998;17:4426-4441.
34. Arthur JS, Fong AL, Dwyer JM, et al. Mitogen- and stress-activated protein kinase 1 mediates cAMP response element-binding protein phosphorylation and activation by neurotrophins. J Neurosci 2004;24:4324-4332.
35. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JS. MSK1 and MSK2 are required for the mitogenand stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 2002;22:2871-2881.
36. Park JM, Greten FR, Wong A, et al. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis - CREB and NF-kB as key regulators. Immunity 2005;23:319-329.
37. Muniyappa H, Das KC. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: A MLK-3-MKK7-dependent mechanism. Cell Signal 2008;20:675-683.
38. Rouse J, Cohen P, Trigon S, et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994;78:1027-1037.
39. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746.
40. Wong S, McLaughlin J, Cheng D, Witte ON. Cell contextspecific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 2003;101:4088-4097.
41. Sanchez-Arevalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, et al. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J 2005;387:231-238.
42. Bandyopadhyay G, Biswas T, Roy KC, et al. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood 2004;104:2514-2522.
43. Mayer IA, Verma A, Grumbach IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-a in BCR-ABL-expressing cells. J Biol Chem 2001;276:28570-28577.
44. Kohmura K, Miyakawa Y, Kawai Y, Ikeda Y, Kizaki M. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. J Cell Physiol 2004;198:370-376.
45. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667-4679.
46. Makino C, Sano Y, Shinagawa T, Millar JB, Ishii S. Sin1 binds to both ATF-2 and p38 and enhances ATF-2- dependent transcription in an SAPK signaling pathway. Genes Cells 2006;11:1239-1251.
47. Wu Z, Woodring PJ, Bhakta KS, et al. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol 2000;20:3951-3964.
48. Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 1997;386:296-299.